In the Press

Air pollution may raise risk of positive COVID-19 test

An observational JAMA Network Open study today involving young adults in Sweden suggests that short-term exposure to even relatively low levels of air pollution is tied to a higher risk of later testing positive for COVID-19, likely by worsening symptoms in those already infected.


Largest study of whole genome sequencing data reveals 'treasure trove' of clues about causes of cancer

DNA analysis of thousands of tumors from NHS patients has found a 'treasure trove' of clues about the causes of cancer, with genetic mutations providing a personal history of the damage and repair processes each patient has been through.


Association between Ozone and Hospitalization for Acute Respiratory Diseases in Children Less than 2 Years of Age

The association between summertime ozone concentrations and hospital admissions for respiratory problems in adults has been well documented (1–21). Specifically, elevated summertime levels have been associated with increased hospital admissions in Montreal, Quebec (20).


CDC advisers discuss future of COVID-19 booster shots

Though all Americans age 50 and older are now eligible to get a second booster of COVID-19 vaccine, the Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) said some groups may benefit more than others from the shot.


New NARMS report shows rising resistance in Salmonella, Campylobacter

The latest data from a national surveillance system that monitors foodborne bacterial pathogens for antimicrobial resistance (AMR) shows some concerning changes in resistance patterns among serotypes of Salmonella.


2022 Detections of Highly Pathogenic Avian Influenza in Wild Birds

Wild birds can be infected with HPAI and show no signs of illness.


Novel Drivers of Virulence in Clostridioides difficile Identified via Context-Specific Metabolic Network Analysis

The pathogen Clostridioides difficile causes toxin-mediated diarrhea and is the leading cause of hospital-acquired infection in the United States.


AstraZeneca's Evusheld slashes risk of symptomatic COVID-19 up to 83%

AstraZeneca's monoclonal antibody combination tixagevimab-cilgavimab (Evusheld) reduced the risk of symptomatic COVID-19 infection by 83% over placebo at a median follow-up of 6 months, finds a phase 3 randomized clinical trial published yesterday in the New England Journal of Medicine.


A messenger substance considered to be inflammatory can alleviate asthma symptoms

The messenger substance interleukin-3 produced by the body was previously considered to be pro-inflammatory in bronchial asthma.


Study finds disparities in improper antibiotic prescribing

A study to be presented at the upcoming European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2022) shows high rates of inappropriate antibiotic prescribing for older Americans, Blacks, and Hispanics.


none 08:00 AM - 05:00 PM 08:00 AM - 05:00 PM 08:00 AM - 05:00 PM 08:00 AM - 05:00 PM 08:00 AM - 05:00 PM 08:00 AM - 05:00 PM 08:00 AM - 05:00 PM others https://g.page/r/CcoVFDGYiftXEAg/review https://www.facebook.com/Healthy-Builds-West-Palm-106299645058480/reviews/?ref=page_internal